TEVA announced on July 27th its intention to withdraw its unsolicited expression of interest to acquire rival Mylan N.V., a leading global pharmaceutical company with a growing portfolio of around 1,400 generic pharmaceuticals and brand medications.
A CRA team led by Raphaël De Coninck and including Elina Koustoumpardi, Roman Fischer, Mikaël Hervé, Nitika Bagaria, Guillaume Débarbat, and Ilia Karmanov provided economic support to Mylan in its antitrust defense in front of the European Commission against the attempted hostile take-over.
The economics of 5G deployment in the “race” to 5G: The state of 5G in the US, South Korea, and other countries
As regulators in various countries consider when and how much spectrum to allocate for 5G services, valuable lessons can be learned from the experiences of 5G...